Japan’s decision to cut the reimbursement price of Ono Pharmaceutical Co. Ltd./Bristol-Myers Squibb Co.'s cancer drug Opdivo (nivolumab) by 50% – the maximum allowable reduction – could signal a tough new effort by the government on prescription drug costs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?